

## TheraPEAK® Lymphocyte Separation Medium

### General information

---

#### Contents:

Section	Description	Page
I	Introduction	1
II	Protocol	1
III	Ordering Information	1
IV	Storage	1
V	Contact Us	2
VI	Product Use Statement	2

#### I. Introduction

Lonza's TheraPEAK® Lymphocyte Separation Medium is a solution used to isolate lymphocytes from whole blood, buffy coats, or other cell populations by density-gradient centrifugation. Lonza's TheraPEAK® Lymphocyte Separation Medium is a mixture of Ficoll® and sodium diatrizoate (Hypaque) with a density adjusted to 1.077 g/mL. Lymphocyte separation is used in preparing cells for CAR-T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, and other forms of adoptive immunotherapy. Lonza's TheraPEAK® Lymphocyte Separation Medium is designed for use in GMP manufacturing, helping ensure proper safety and quality standards for cell therapy procedures. This product is sterile and tested to target osmolality and endotoxin specifications to maintain high cell quality during downstream processing.

#### II. Protocol

1. Anticoagulated blood (citrated or heparinized) should be used.  
**NOTE:** Always treat human and other primate source material as potentially infectious and take safety precautions.
2. Dilute blood 1:1 with calcium-magnesium-free PBS and layer 9 mL onto 6 mL Lymphocyte Separation Medium. Use a clear plastic centrifuge tube with a cap. For large volumes use a similar ratio of diluted blood to Lymphocyte Separation Medium.

3. Centrifuge at 400 x g for 15 minutes.
4. Remove plasma-PBS without disturbing the interface.
5. Collect the interface with a cannula and dilute to 20 mL in serum-free medium, such as RPMI 1640.
6. Centrifuge at 70 x g for 10 minutes.
7. Discard supernatant fluid and resuspend pellet in 2 – 3 mL serum-free medium.
8. Count nucleated cells on a hemocytometer or electronic counting device.
9. Lymphocytes will be concentrated at the interface, along with some platelets and monocytes. Granulocytes will be found mostly in the Lymphocyte Separation Medium and erythrocytes will pellet at the bottom of the tube.

#### III. Ordering information

Catalog number	Product	Size
BP17-829E	TheraPEAK® Lymphocyte Separation Medium	100 mL bottle

---

#### IV. Storage

This product should be stored at +15 to +30 °C.

## V. Contact Us

### North America

Customer Service + 1800 638 8174 (toll free)

[Order.us@lonza.com](mailto:Order.us@lonza.com)

Scientific Support + 1800 521 0390 (toll free)

[Scientific.Support@lonza.com](mailto:Scientific.Support@lonza.com)

### Europe

Customer Service + 32 87 321 611

[Order.Europe@lonza.com](mailto:Order.Europe@lonza.com)

Scientific Support + 49 221 99199 400

[Scientific.support.eu@lonza.com](mailto:Scientific.support.eu@lonza.com)

## VI. Product Use Statement

TheraPEAK® Products are not for human or animal *in vivo* or diagnostic use, including use as a diluent or as an excipient. All TheraPEAK® Products are produced according to applicable GMP standards and follow the USP/EP guidance for cell and gene therapy raw materials. It is the end user's responsibility to ensure full compliance with applicable regulations based on their use of Lonza's products in their specific process. All trademarks belong to Lonza Group Ltd. and its affiliates (collectively and individually, "Lonza"), and are registered in the USA, EU and/or CH, or used in common law, or belong to third-party owners and are used for only informational purposes. All third-party copyrights have been reproduced with permission from their owners. User assumes all risks of product use and handling. Lonza makes efforts to include accurate and up-to-date information. However, Lonza makes no representations or warranties, express or implied, including as to the accuracy or completeness of information, or the use or handling of these products. The user is responsible for determining if the products supplied by Lonza and the information and recommendations given by Lonza are (i) suitable for intended process or purpose, (ii) are in compliance with environmental, health and safety regulations, and other regulations in the regions and countries where they are purchased, offered for sale, marketed, sold, and used and (iii) will not infringe any third party's intellectual property rights. The user bears the sole responsibility for determining the existence of any such third-party rights, as well as obtaining any necessary licenses and approvals. For more information, including regarding legal disclaimers, Lonza's intellectual property rights, and how Lonza collects, uses and protects personal information: [www.lonza.com/legal](http://www.lonza.com/legal), <https://www.lonza.com/about-us/strategy/intellectual-property> and [www.lonza.com/privacy](http://www.lonza.com/privacy).  
©2026 Lonza, Inc. All rights reserved. CT-OP010 02/26